All In Biotech

Drug Trial Radar · NCT03502148

Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jun 19, 2018

Primary completion

Oct 27, 2019

Study completion May 6, 2020

Sponsor

Lead sponsor
Privo TechnologiesIndustry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Apr 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits. These 4 treatment visits were scheduled to occur during the 3 weeks prior to the standard of care tumor resection. Funding Source: FDA OOPD

Conditions

  • Oral Squamous Cell Carcinoma

Interventions

  • PRV111 (Cisplatin Transmucosal System)Drug

    Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor ResponsesTime frame: Subjects were evaluated for efficacy during the 4 treatment visits in the 21 days prior to surgery
  2. Determine a Safe Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Dose-Limiting ToxicitiesTime frame: 4 treatment visits in the 21 days prior to surgery

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced ENT and Allergy

    Louisville, Kentucky

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • Ben Taub Hospital

    Houston, Texas

  • Memorial Hermann Hospital

    Houston, Texas

  • The University of Texas Health Science Center School of Dentistry

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.